Claim: The immunomodulatory imide drug class includes thalidomide which has a protein binding of 55–65% and has hydrolized metabolites.
Evidence: The IMiD class includes thalidomide and its analogues (lenalidomide, pomalidomide, iberdomide, and apremilast). Protein binding 55–65% Metabolites Hydrolized metabolites